The Committee for Medicinal Products for Human Use (CHMP) issued an opinion supporting Mayzent (siponimod) as an oral treatment specifically for adults with active secondary progressive multiple sclerosis (SPMS) in the European Union. Opinions released by CHMP, an arm of the European Medicines Agency (EMA), carry weight and are…
Alexa
Recommended Posts
- Alcohol, caffeine may ease some MS symptoms but worsen others
- Making peace with artificial intelligence being used in healthcare settings
- Study highlights strengths, limitations of mouse models used to study MS
- Enrollment in MS imaging study reaches halfway mark
- A letter to my loved ones about supporting someone with MS